<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114487">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01612767</url>
  </required_header>
  <id_info>
    <org_study_id>G110147</org_study_id>
    <nct_id>NCT01612767</nct_id>
  </id_info>
  <brief_title>BIOHELIX-I Bare Metal Stent Study</brief_title>
  <acronym>BIOHELIX-I</acronym>
  <official_title>The Treatment of Coronary Artery Lesions Using the PRO-Kinetic Energy Cobalt-Chromium, Bare-Metal Stent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotronik, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the safety and efficacy of the investigational
      BIOTRONIK PRO-Kinetic Energy stent in subjects with atherosclerotic disease of native
      coronary arteries.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint for the study is the target vessel failure rate</measure>
    <time_frame>9 months post index procedure</time_frame>
    <description>Target vessel failure is defined as cardiac death, myocardial infarction and ischemia-driven target vessel revascularization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Failure rate</measure>
    <time_frame>1, 12, 24 and 36 months</time_frame>
    <description>Target vessel failure is defined as cardiac death, myocardial infarction (MI) and ischemia-driven target vessel revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Failure rate - contribution of individual event types</measure>
    <time_frame>1, 12, 24 and 36 months</time_frame>
    <description>Contribution of each event type (cardiac death, myocardial infarction (MI) and ischemia-driven target vessel revascularization) to composite rate of target vessel failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall TVR rate</measure>
    <time_frame>1, 9, 12, 24 and 36 months</time_frame>
    <description>Overall target vessel revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion failure rate</measure>
    <time_frame>1, 9, 12, 24 and 36</time_frame>
    <description>Target lesion failure including contribution of each event to composite rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall target lesion revascularization rate</measure>
    <time_frame>1, 9, 12, 24 and 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of all-cause mortality and all-cause MI</measure>
    <time_frame>1, 9, 12, 24 and 36</time_frame>
    <description>This includes contribution of each event to overall composite rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis rate</measure>
    <time_frame>1, 9, 12, 24 and 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Index procedure success</measure>
    <time_frame>1, 9, 12, 24 and 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success during the index procedure</measure>
    <time_frame>Index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion success during the index procedure</measure>
    <time_frame>Index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angina pectoris classification</measure>
    <time_frame>1, 9, 12, 24 and 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of all adverse events not included in the evaluation of the primary endpoint</measure>
    <time_frame>1, 9, 12, 24 and 36</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">329</enrollment>
  <condition>Coronary Arteries Disease</condition>
  <arm_group>
    <arm_group_label>Pro-Kinetic Energy Stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PRO-Kinetic Energy Stent</intervention_name>
    <description>Coronary artery stent implant</description>
    <arm_group_label>Pro-Kinetic Energy Stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For a subject to be enrolled in the study and considered for the index procedure, the
        following initial inclusion criteria must be met:

          -  Age ≥ 18 years

          -  Willingness to comply with study follow-up requirements

          -  Candidate for a PCI procedure

          -  Candidate for coronary artery bypass graft surgery

          -  Documented evidence of stable or unstable angina pectoris or positive functional
             ischemia study (e.g. exercise treadmill test, thallium stress test, SPECT, stress
             echocardiogram or cardiac CT) Stable angina pectoris is defined as a documented
             Canadian Cardiovascular Society Classification of I, II, III or IV Unstable angina
             pectoris is defined as a documented Braunwald Classification of B &amp; C, I, II, III

          -  Written informed consent

        For a subject to receive an investigational stent, the following procedure-related
        criteria must be met:

          -  De novo or restenotic lesion in a native coronary artery; restenotic lesions must
             have been previously treated with only standard PTCA (treatment must be &gt; 12 months
             prior to the index procedure)

          -  Target lesion must be in a major coronary artery (target vessel). The target vessel
             includes the entire territory of the left anterior descending artery, left circumflex
             artery or right coronary artery and any major side branch of the artery.

          -  A maximum of one target lesion and one non-target lesion may be treated per subject.
             The lesions must be located in separate coronary arteries, with treatment of the
             non-target lesion occurring first using commercially available therapy (with
             exception of brachytherapy).

          -  Lesions may be one solid lesion or a series of multiple, smaller lesions to be
             treated as one lesion

          -  Target lesion must be treatable with a single investigational stent; an additional
             stent may be used when treating a vessel dissection or another similar
             intra-procedure complication (use of investigational stent preferred)

          -  Angiographic evidence of ≥ 50% and &lt; 100% stenosis (by operator visual estimate) with
             a TIMI flow &gt; 1

          -  Target lesion length of ≤ 31 mm by operator visual estimate

          -  Target vessel reference diameter of 2.25 mm to 4.0 mm by operator visual estimate

        Exclusion Criteria:

        For a subject to be enrolled in the study and considered for the index procedure, the
        following initial exclusion criteria must not be present:

          -  Baseline LVEF of &lt; 30%; LVEF may be measured and assessed by standard-of-care
             echocardiography procedures within 90 days of the index procedure or by a left
             ventriculogram prior to the index procedure (operator visual assessment).

          -  PCI in any vessel 30 days prior to the index procedure or planned for within 30 days
             after the index procedure

          -  Stroke or transient ischemic attack within the last 6 months prior to enrollment

          -  Intolerance to contrast agents that cannot be medically managed and/or intolerance to
             antiplatelet, anticoagulant or thrombolytic medications

          -  Refusal of blood transfusions

          -  Any other medical condition, that in the opinion of the investigator, poses an
             unacceptable risk for implant of a stent according to the study indications

          -  Pregnant, planning to become pregnant or nursing during the course of the study.
             Women of child-bearing potential must have a negative blood pregnancy (beta hCG)
             test. Female subjects who are surgically sterile or post-menopausal are exempt from
             having a pregnancy test.

          -  Known allergy to L-605 CoCr alloy (cobalt, chromium, tungsten and nickel) or
             amorphous silicon carbide

          -  Life expectancy of less than one year

          -  Participation in any other clinical investigational device or drug study.

          -  Subjects may be concurrently enrolled in a post-market study, as long as the
             post-market study device, drug or protocol does not interfere with the
             investigational treatment or protocol of this study.

        For a subject to receive an investigational stent the following procedure-related criteria
        must not be present:

          -  Documented diagnosis of an acute MI within 72 hours of the index procedure and an
             elevation of Troponin or CKMB above the URL (CKMB measurement is not required if CK
             is normal) at the time of the index procedure (99th percentile of the individual
             investigative site's normal reference population)

               -  For subjects with stable angina and elevated Troponin, CKMB &lt;99% URL is required

          -  ECG changes consistent with an acute MI within 72 hours of the index procedure. ECG
             changes consistent with an acute MI include:

        &gt; 1 mm ST segment elevation or depression in consecutive leads New LBBB Development of
        pathological Q-waves in two contiguous leads of the ECG

          -  Acute coronary syndrome with baseline Troponin &gt; 99% URL

          -  INR ≥ 1.6

          -  Concomitant renal failure with serum creatinine level &gt; 2.5 mg/dL

          -  Unresolved neutropenia (white blood cell count &lt; 3,000 / µL), thrombocytopenia
             (platelet count &lt; 100,000 / µL) or thrombocytosis (platelet count &gt; 700,000 / µL)

          -  Unprotected left main CAD (&gt; 50% diameter stenosis by operator visual estimate)

          -  Target vessel has been treated with any PCI procedure (e.g. PTCA, stent, cutting
             balloon, atherectomy, etc.) within 12 months prior to the index procedure

          -  Target lesion has been treated with a stent, cutting balloon or atherectomy any time
             prior to the index procedure or has been treated with PTCA within 12 months prior to
             the index procedure

          -  Target vessel treated with brachytherapy anytime prior to index procedure

          -  Planned PCI in the target vessel within 9 months after the index procedure

          -  Target vessel has a non-target lesion with a &gt; 50% stenosis that requires treatment
             during the index procedure

          -  Lesions preventing distal perfusion (TIMI flow 0 and 1) prior to wire crossing

          -  Target lesion is in the left main coronary artery or within 2 mm of the origin of the
             left anterior descending artery or left circumflex artery by operator visual estimate

          -  Target lesion is located within a saphenous vein graft or arterial graft

          -  Target lesion involves a bifurcation - lesion is located in a major coronary artery
             and involves a side branch with a diameter &gt; 2 mm (by operator visual estimate)

          -  Presence of a complication following pre-dilatation of target lesion

          -  Presence of a complication following treatment of a non-target lesion (if applicable)

          -  Presence of a target vessel/lesion that has excessive tortuousity/angulation or is
             severely calcified preventing complete inflation of an angioplasty balloon

          -  Angiographic evidence of thrombus within the target lesion

          -  Target lesion is located within an aneurysm or associated with an aneurysm in the
             vessel segment either proximal or distal to the target lesion

          -  Use of cutting balloons, atherectomy or ablative devices immediately prior to
             investigational stent placement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saurabh Gupta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Concord</city>
        <state>California</state>
        <zip>94520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <zip>06810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lewiston</city>
        <state>Maine</state>
        <zip>04240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Takoma Park</city>
        <state>Maryland</state>
        <zip>20912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gastonia</city>
        <state>North Carolina</state>
        <zip>28054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <zip>75069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mechanicsville</city>
        <state>Virginia</state>
        <zip>23116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bad Segeberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Essen</city>
        <zip>D-45138</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ludwigshafen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
    <country>Germany</country>
    <country>Latvia</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 12, 2016</lastchanged_date>
  <firstreceived_date>June 4, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>de novo coronary lesions</keyword>
  <keyword>restenotic coronary lesions</keyword>
  <keyword>coronary arteries</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
